Notice of Proposed Settlement of Stockholder Litigation. Click here for information.
Financials & Filings
OTCQB: INTI
PRICE:
This section of the Inhibitor Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Inhibitor Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
| Beta | (0.48) |
|---|---|
| Shares Outstanding | 171.8M |
| Average Volume (10 days) | 3.3K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | N/A |
|---|
| Strong Buy | 0 | |
|---|---|---|
| Buy | 0 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Debra Peattie Director | 580,646 Acquire Dec 22, 2020 |
|---|---|
Virca Nicholas Ceo/President | 125,000 Acquire Dec 22, 2020 |
Robert Martin Director | 754,839 Acquire Dec 22, 2020 |
Watson W. Director | 1,306,452 Acquire Dec 22, 2020 |
Garrison J. Hasara Cfo And Treasurer | 125,000 Acquire Dec 22, 2020 |
Get Important News and Updates by Email